Table 4. Patients receiving rituximab... | American Society of Hematology

Table 4.

Patients receiving rituximab prophylaxis on 3 or more occasions

Patient	Age at episode (y)	Sex	Ethnic group	Treatment-free survival (mo)
Patient	Age at episode (y)	Sex	Ethnic group	After first episode		After second episode		After third episode		After fourth episode		After fifth episode
1	46-48	F	SE	12	R	14	I	6	I*
2	54-57	F	AC	10	R	17	S	10	I*
3	54-56	F	AC	11	S	12	S	71	S*
4	64-66	F	AC	12	R	11	R	10	I*
5	25-30	M	W	38	S	25	R	3	I*
6	41-47	F	AC	14	S	9	R	10	R	3	S*
7	31-39	F	W	29	S	30	S	31	R	12	I*
8	24-29	F	AC	14	S	13	R	13	R	12	R	9	I*

Patient	Age at episode (y)	Sex	Ethnic group	Treatment-free survival (mo)
Patient	Age at episode (y)	Sex	Ethnic group	After first episode		After second episode		After third episode		After fourth episode		After fifth episode
1	46-48	F	SE	12	R	14	I	6	I*
2	54-57	F	AC	10	R	17	S	10	I*
3	54-56	F	AC	11	S	12	S	71	S*
4	64-66	F	AC	12	R	11	R	10	I*
5	25-30	M	W	38	S	25	R	3	I*
6	41-47	F	AC	14	S	9	R	10	R	3	S*
7	31-39	F	W	29	S	30	S	31	R	12	I*
8	24-29	F	AC	14	S	13	R	13	R	12	R	9	I*

AC, Afro-Caribbean; F, female; I, intermediate dose; M, male; R, reduced dose; S, standard dose; SE, Southeast Asian; W, white.

Currently in remission, not requiring re-treatment.